OBJECTIVES

To perform a budget impact analysis (BIA) of introducing Olaparib as maintenance therapy in BRCA-mutated (BRCAm) women with platinum sensitive recurrent ovarian cancer (PSROC), from the perspective of the National Oncologic Institute of Panama (ION)

METHODS

A global BIA model was used to analyse over a 5-year time horizon the change in the ION´s expenditure following the adoption of Olaparib as maintenance therapy in BRCAm patients with PSROC. The financial impact for each year was estimated by comparing the cost of changing the current standard of care (“watch and wait”) with the adoption of Olaparib for the whole targeted population (considering an 100% uptake of Olaparib annually). National epidemiological data was used to determine the patient population. Clinical efficacy and safety outcomes were obtained from the clinical study report for Study 19 (NCT00753545). Healthcare resource use was determined through local expert validation. Panama does not have a national healthcare tariff. Therefore, costs such as patient follow-up, serious adverse events management, and subsequent chemotherapy were homologated with the Costa Rican national tariff based on macroeconomic similarities of both healthcare systems. BRCAm testing costs were not included in the analysis. The analysis did not considered costs associated with induction therapy, subsequent therapy and end-of-life care (assuming these costs would have minimal budget impact).

RESULTS

The annual incremental costs resulting from switching “watch and wait” to Olaparib were $476,087; $490,356; $490,269; $497,721 and $505,287 (years 1 to 5).

CONCLUSIONS

The analysis suggests that the clinical benefit of replacing “watch and wait” strategy with Olaparib in a group of patients without any current therapeutic option available (BRCAm women with PSROC), provides predictable costs for supporting the planning and decision-making process of payers in Panama.